Lenvatinib Receives FDA Approval for Unresectable Hepatocellular Carcinoma

​ The FDA has approved lenvatinib capsules (Lenvima®, Eisai Inc.) for first-line treatment in patients with unresectable hepatocellular carcinoma (HCC). Lenvatinib was previously granted approval for use in patients with locally recurrent or metastatic progressive, radioactive iodine-refractory differentiated thyroid cancer; it was also approved in combination with everolimus to treat advanced renal cell carcinoma. Approval of lenvatinib for unresectable HCC was based on an international, multic...
Continue reading

Dabrafenib/Trametinib Approved for BRAF V600E-Positive Anaplastic Thyroid Cancer

​ Dabrafenib plus trametinib (Taflinar and Mekinist, Novartis Pharmaceuticals Corp.) has received approval for the treatment of patients with BRAF V600E-positive, locally advanced or metastatic anaplastic thyroid cancer (ATC) in the absence of other satisfactory locoregional treatment options. Approval was based on findings from the 9-cohort, nonrandomized BRF117019 trial. In 23 patients with ATC, dabrafenib/trametinib was associated with an overall response rate of 61%, a complete response rate...
Continue reading

Best Practices in Thyroid Cancer Management With Jochen H. Lorch, MD, MS

Thyroid cancer is one of the most prevalent cancers in the United States. An estimated 56,870 new cases are diagnosed annually, and 2,010 people die of the disease. Thyroid cancer is typically more aggressive in men than women and becomes increasingly lethal in those older than age 40. The dearth of data from well-designed trials has led to confusion over the optimal management strategies for individual patients. In this interview, Jochen Lorch, MD, MS, Assistant Professor of Medicine at Harvard...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.